Werewolf Therapeutics, Inc.

What they do

Werewolf Therapeutics uses its proprietary PREDATOR platform to design conditionally activated INDUKINE and INDUCER molecules that stimulate the immune system to treat cancer. Its most advanced candidates are WTX-124 (IL-2) and WTX-330 (IL-12), both in clinical trials for solid tumors. The company also has preclinical INDUCER T cell engager candidates targeting STEAP1 and CDH6. As of 2026, it has no commercial products and no revenue from product sales.

Revenue drivers

• Collaboration revenue (asset sale) — In Q2 2026, the company recognized $21.0 million in collaboration revenue from selling its JZP898 program to Jazz Pharmaceuticals. This was the only revenue recognized in the quarter; no revenue was recognized in Q2 2025.
• No product revenue — All product candidates are in clinical or preclinical development. The company has not generated any revenue from product sales.

Recent performance

For Q2 2026, Werewolf reported net income of $3.7 million, compared to a net loss of $18.0 million in Q2 2025. Cash and cash equivalents were $22.0 million as of June 30, 2026, down from $46.5 million at March 31, 2026. Research and development expenses fell to $6.2 million from $13.1 million, while G&A expenses rose to $7.7 million from $4.4 million. The company used only $4.0 million in cash for operations in the first half of 2026, reflecting the restructuring.

Strategy

Management is pursuing strategic alternatives, including a possible sale, merger, asset sale, or licensing deal, with Piper Sandler as exclusive financial advisor. As part of this, the company reduced its workforce by 64% in February 2026 and expects a one-time charge of about $4.1 million. It also sold its JZP898 program to Jazz Pharmaceuticals and repaid all amounts owed under its loan and security agreement with K2 HealthVentures. The company continues to advance its clinical programs, with WTX-124 and WTX-330 data updates expected later in 2026.

Risks

• Going concern — Management has stated there is substantial doubt about the company's ability to continue as a going concern for at least twelve months from the filing date; as of June 30, 2026, cash was $22.0 million and accumulated deficit was $485.3 million.
• Funding shortfall — The company expects existing cash to fund operations only into the second quarter of 2027, and no dedicated source of liquidity exists beyond an ATM offering that may be limited by S-3 rules.
• Strategic alternatives uncertainty — There is no assurance that the strategic review process, which includes possible sale or merger, will result in any transaction, and a failure could force the company to curtail or cease operations.
• Clinical and regulatory risk — WTX-124 and WTX-330 are still in early-stage trials; clinical data may not support approval, and any delays or failures could materially harm the business.

Outlook

Management expects to provide additional updates on the strategic alternatives process and clinical data for WTX-124 and WTX-330 in the second half of 2026. Based on current plans, the company believes it can fund operations into the second quarter of 2027. However, substantial doubt remains about long-term viability without additional funding or a strategic transaction.